Hemkens et al. found that, considering the connections between insulin doses and cancer progression [36], the cancer incidence with insulin-glargine use was higher than that when using endogenous insulin [39], especially in the case of prostate and breast cancer [39,40,41]. This evidence concerns the gene INS and breast carcinoma.